This trial is seeking approximately 650 participants, who will be randomly assigned into one of two different groups (or cohorts). Cohorts are groups of participants who meet specific criteria for Multiple Myeloma. Before being separated into different arms (randomization), all participants in the study will receive 5-6 cycles of Bortezomib, Lenalidomide, and Dexamethasone (VRd). Participants will need to visit the study site four times during each 21 day cycle. 

During these initial cycles before being placed into different groups, participants will receive:

• Bortezomib, given by subcutaneous injection, every three days during the first half of each cycle.
• Lenalidomide, given by mouth daily, for the first two weeks of each cycle.
• Dexamethasone, given by mouth during the first two weeks of each cycle.

Treatment Involved

The investigational medication is an investigational autologous chimeric antigen receptor T cell (CAR-T) therapy. This means it’s a therapy made from your own T cells, to try and kill your cancerous multiple myeloma cells. In this study, your doctor will draw whole blood and separate it into its parts- plasma and white blood cells (T-cells). This process is called apheresis.  These T cells will then be changed in a laboratory by giving them some new genetic material. These T cells will then be given back to you by an intravenous infusion.